Ceftaroline fosamil
- Generic Name
- Ceftaroline fosamil
- Brand Names
- Teflaro, Zinforo
- Drug Type
- Small Molecule
- Chemical Formula
- C22H21N8O8PS4
- CAS Number
- 229016-73-3
- Unique Ingredient Identifier
- 7P6FQA5D21
- Background
Ceftaroline fosamil is a cephalosporin antibacterial indicated for the treatment of the following infections caused by designated susceptible bacteria:
Acute bacterial skin and skin structure infections.
Community-acquired bacterial pneumonia.
- Indication
Ceftaroline fosamil is indicated for the treatment of patients with the following infections caused by susceptible isolates of the designated microorganisms.
- Associated Conditions
- Acute Bacterial Skin and Skin Structure Infection (ABSSSI), Community-Acquired Bacterial Pneumonia (CABP)
- Associated Therapies
- -
The Use of Ceftaroline as Surgical Prophylaxis in Surgery With Risk of MRSA Infection
- First Posted Date
- 2014-12-03
- Last Posted Date
- 2015-12-02
- Lead Sponsor
- University of Cincinnati
- Target Recruit Count
- 500
- Registration Number
- NCT02307006
- Locations
- 🇺🇸
West Chester Hospital, West Chester, Ohio, United States
🇺🇸University of Cincinnati Medical Center, Cincinnati, Ohio, United States
Evaluation of Ceftaroline Fosamil vs Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections.
- Conditions
- Interventions
- First Posted Date
- 2014-07-28
- Last Posted Date
- 2017-09-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 4
- Registration Number
- NCT02202135
- Locations
- 🇹🇷
Research site, Izmir, Turkey
Ceftaroline in the Treatment of Bone and Joint Infections
- First Posted Date
- 2013-12-09
- Last Posted Date
- 2014-08-07
- Lead Sponsor
- Orlando Health, Inc.
- Registration Number
- NCT02005068
- Locations
- 🇺🇸
Orlando Regional Medical Center, Orlando, Florida, United States
Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients
- First Posted Date
- 2012-11-28
- Last Posted Date
- 2023-05-03
- Lead Sponsor
- Henry Ford Health System
- Target Recruit Count
- 100
- Registration Number
- NCT01734694
- Locations
- 🇺🇸
Henry Ford Hospital, Detroit, Michigan, United States
Safety and Efficacy Study of Ceftaroline in Subjects With Staphylococcus Aureus Bacteremia or With Persistent Methicillin-Resistant Staphylococcus Aureus Bacteremia
- Conditions
- Interventions
- First Posted Date
- 2012-10-05
- Last Posted Date
- 2014-07-31
- Lead Sponsor
- Forest Laboratories
- Target Recruit Count
- 56
- Registration Number
- NCT01701219
- Locations
- 🇺🇸
Investigational Site, Roanoke, Virginia, United States
Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Complicated Community Acquired Pneumonia (CABP)
- Conditions
- Interventions
- First Posted Date
- 2012-08-21
- Last Posted Date
- 2015-11-01
- Lead Sponsor
- Forest Laboratories
- Target Recruit Count
- 40
- Registration Number
- NCT01669980
- Locations
- 🇬🇪
Investigational Site 3, Tbilisi, Georgia
🇺🇦Investigational Site, Kyiv, Ukraine
🇦🇷Investigative Site, Buenos Aires, Argentina
Safety and Efficacy Study of Ceftaroline in Elderly Subjects With Community-Acquired Bacterial Pneumonia
- Conditions
- Interventions
- First Posted Date
- 2012-08-16
- Last Posted Date
- 2013-02-11
- Lead Sponsor
- Forest Laboratories
- Registration Number
- NCT01666743
Pharmacokinetics of Ceftaroline in Normal and Obese Subjects
- First Posted Date
- 2012-07-24
- Last Posted Date
- 2013-03-14
- Lead Sponsor
- Keith A. Rodvold
- Target Recruit Count
- 32
- Registration Number
- NCT01648127
- Locations
- 🇺🇸
University of Illinois at Chicago, Chicago, Illinois, United States
Evaluation of Ceftaroline Fosamil Versus a Comparator in Adult Subjects With Community-acquired Bacterial Pneumonia (CABP) With Risk for Methicillin-resistant Staphylococcus Aureus
- Conditions
- Interventions
- First Posted Date
- 2012-07-20
- Last Posted Date
- 2016-02-01
- Lead Sponsor
- Forest Laboratories
- Target Recruit Count
- 49
- Registration Number
- NCT01645735
- Locations
- 🇺🇦
Investigational Site, Zaporizhzhya, Ukraine
Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Community Acquired Bacterial Pneumonia (CABP)
- Conditions
- Interventions
- First Posted Date
- 2012-02-10
- Last Posted Date
- 2015-01-13
- Lead Sponsor
- Forest Laboratories
- Target Recruit Count
- 161
- Registration Number
- NCT01530763
- Locations
- 🇺🇦
Investigational Site, Zaporizhia, Ukraine
🇬🇪Investigational Site2, Tbilisi, Georgia
🇬🇪Investigational Site3, Tbilisi, Georgia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.